Morgan Stanley’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-2,244
Closed -$272K 7782
2023
Q1
$272K Sell
2,244
-26,760
-92% -$3.08M ﹤0.01% 5564
2022
Q4
$3.31M Buy
29,004
+26,180
+927% +$2.89M ﹤0.01% 4105
2022
Q3
$289K Sell
2,824
-2,373
-46% -$251K ﹤0.01% 5549
2022
Q2
$527K Sell
5,197
-44,328
-90% -$4.83M ﹤0.01% 5390
2022
Q1
$5.77M Buy
49,525
+44,085
+810% +$5.1M ﹤0.01% 3535
2021
Q4
$626K Buy
+5,440
New +$620K ﹤0.01% 5406
2020
Q4
Sell
-1,906
Closed -$212K 7166
2020
Q3
$212K Sell
1,906
-304
-14% -$34.1K ﹤0.01% 5081
2020
Q2
$230K Buy
+2,210
New +$237K ﹤0.01% 5012

Other funds holding BSX.PRA

Morgan Stanley's BSX.PRA Position: Q2 2023 in Review

Morgan Stanley sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 2,244 shares — an estimated $272K sold.

Morgan Stanley first reported a position in BSX.PRA in Q2 2020 and held it in 8 quarters. The position peaked at $5.77M in Q1 2022. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

  • Morgan Stanley reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
  • Morgan Stanley sold 2,244 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $272K.
  • Morgan Stanley first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2020 and held it in 8 quarters.
  • Morgan Stanley's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $5.77M in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.